Literature DB >> 2163811

The effect of partial noncompliance on the power of a clinical trial.

L S Freedman1.   

Abstract

Noncompliance is an important concern in randomized trials and must be taken into account when calculating sample sizes. The effect of noncompliance is usually assessed through a simple binary model that assumes that the patient either does or does not comply with the allocated treatment. In this article I present an example from cancer prevention, and show that different time courses of noncompliance can have different effects on the power, with widely varying estimates of the sample size required. The time course as well as the level of noncompliance should be considered when planning trials with long-term treatments.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2163811     DOI: 10.1016/0197-2456(90)90010-y

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  6 in total

1.  Noncompliance in randomized controlled trials.

Authors:  Jeevan P Marasinghe; A A W Amarasinghe
Journal:  CMAJ       Date:  2007-06-05       Impact factor: 8.262

2.  Predictors of participant retention in infertility treatment trials.

Authors:  Hongying Kuang; Susan Jin; Tracey Thomas; Lawrence Engmann; Karl R Hansen; Christos Coutifaris; Peter Casson; Gregory Christman; Ruben Alvero; Nanette Santoro; Esther Eisenberg; Michael P Diamond; Richard S Legro; Heping Zhang
Journal:  Fertil Steril       Date:  2015-09-03       Impact factor: 7.329

3.  A Bayesian hierarchical model estimating CACE in meta-analysis of randomized clinical trials with noncompliance.

Authors:  Jincheng Zhou; James S Hodges; M Fareed K Suri; Haitao Chu
Journal:  Biometrics       Date:  2019-04-04       Impact factor: 2.571

4.  Efficacy of the Sentinox Spray in Reducing Viral Load in Mild COVID-19 and Its Virucidal Activity against Other Respiratory Viruses: Results of a Randomized Controlled Trial and an In Vitro Study.

Authors:  Donatella Panatto; Andrea Orsi; Bianca Bruzzone; Valentina Ricucci; Guido Fedele; Giorgio Reiner; Nadia Giarratana; Alexander Domnich; Giancarlo Icardi
Journal:  Viruses       Date:  2022-05-12       Impact factor: 5.818

5.  The interpretation of clinical trials of immediate versus delayed therapy.

Authors:  M Mittlböck; J Whitehead
Journal:  Lifetime Data Anal       Date:  1998       Impact factor: 1.588

6.  Calculating sample size for studies with expected all-or-none nonadherence and selection bias.

Authors:  Michelle D Shardell; Samer S El-Kamary
Journal:  Biometrics       Date:  2009-06       Impact factor: 2.571

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.